A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus
Latest Information Update: 30 Jan 2023
Price :
$35 *
At a glance
- Drugs Omarigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OMNEON
- Sponsors Merck Sharp & Dohme
- 19 Jun 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database
- 30 May 2019 This trial has been completed in Norway, according to European Clinical Trials Database.
- 27 May 2019 This trial has been completed in Croatia, according to European Clinical Trials Database